The deaths were due to acute liver injury, a known risk of Zolgensma and a concern for gene therapies like it.

The company will wind down five trials involving two drug candidates and lay off more staff, prioritizing instead its RNA-editing technology.

The companies could face liability related to their sales of the heartburn drug, which was withdrawn from market in the U.S. and other countries after impurities related to a likely carcinogen were detected.

The study could be critical for a medicine EQRx plans to position as a competitor to Tagrisso. The drug is under review in the U.K., a first for EQRx.

The biotech’s failed attempt to develop an eye disease drug has ended in a reverse merger that gives startup Disc Medicine a fast path to the public markets.

Abecma, which 2Seventy bio helps develop and sell, is currently approved for patients who have tried at least four other medicines for the blood cancer.

The FDA authorized a new plan that could lead to a five-fold increase in available doses. European health officials may follow the agency's lead. 

The deal, worth as much as $2 billion, is the latest sign of industry interest in treatments that harness regulatory T cells, an approach behind several recent biotech startups.

Boston-based Cerevance uses samples of healthy and diseased human brain tissue to find new targets for central nervous system diseases.

The biotech now expects about $2 billion in revenue in 2022, less than half its previous estimates, after sales fell sharply in the second quarter.

The experimental vaccine is the most advanced candidate for the tick-borne disease and, if successful, would be the first to reach the market since withdrawal of GSK’s Lymerix.

Mathai Mammen is leaving to “pursue other opportunities,” J&J said in an abrupt announcement. William Hait, currently head of external innovation, will take Mammen’s place in the interim.